Cerus appoints Andrew Gomperts CBO
This article was originally published in Scrip
Biomedical products company Cerus Corporation has appointed Andrew Gomperts chief business officer and vice-president of business development and marketing. He most recently served as head of corporate and business development at Sangart, and has prior experience at Idealab, Prometheus Laboratories and McKinsey & Company.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.